title: Rat and human liver cytochrome P-450 isoform metabolism of ecteinascidin 743 does not predict gender-dependent toxicity in humans.
abstract: Ecteinascidin 743 (ET743, NSC648766) is a marine natural product with potent in vivo activity in human xenograft models. Hepatotoxicity was the most prominent toxicity in preclinical studies and was greater in female rats than in male rats. To assess the potential implications for human toxicities, the in vitro metabolism of ET743 was characterized using rat and human preparations. NADPH-dependent ET743 metabolism was greater with male rat liver microsomal preparations than with preparations from female rats and was induced by pretreatment of rats with phenobarbital and dexamethasone but not by pretreatment with 3-methylcholanthrene. Rat and human microsomal metabolism of ET743 was reduced in the presence of chemical CYP3A inhibitors or antirat CYP3A2 antiserum and to a much lesser extent by CYP2E, CYP2C, and CYP2A inhibitors. In human liver panel studies, ET743 disappearance was highly correlated with CYP3A activities and to a lesser extent with CYP2C activities. ET743 was metabolized by a number of cDNA-expressed rat P-450 isoforms, including male-predominant CYP2A2 and CYP3A2. ET743 was metabolized by cDNA-expressed human CYP3A4 and to a much lesser extent by CYP2C9, CYP2D6, and CYP2E1 preparations. Three oxidative metabolites were detected in cDNA-expressed isoform incubations, including the N-demethylated metabolite ET729 and two additional products characterized by laser capture-mass spectrometry analyses. The plasma pharmacokinetics and biliary excretion of ET743 were characterized in rats. There were no gender-dependent differences in half-life or total body clearance values. Although very modest, the biliary excretion of ET743 in male rats (0.48%) was greater than in female rats (0.28%). In contrast, the biliary excretion of the cytotoxic N-demethylated metabolite ET729 was 5-fold greater in the female rat (1.05% of dose) than in the male rat (0.19% of dose). Biliary excretion of ET729 may contribute to the hepatic toxicity in rats. These data are consistent with a major role for CYP3A isoforms in ET743 rat and human metabolism. Although there are conflicting data in the literature, expression of CYP3A isoforms in human tissues and elimination of CYP3A substrates have not been shown to vary substantially by gender. There are no indications that the other CYP isoforms implicated in ET743 metabolism are expressed differently in males and females. Thus, although it is not possible to rule out gender differences in ET743 human toxicities, our data do not predict major gender-dependent differences in the toxicity of ET743 based on metabolism.
authors.affiliation: Department of Oncology, Division of Developmental Oncology Research, Mayo Clinic, Rochester, Minnesota 55905, USA.
authors.forename: Joel M
authors.initials: JM
authors.lastname: Reid
authors.forename: Mary J
authors.initials: MJ
authors.lastname: Kuffel
authors.forename: Stacie L
authors.initials: SL
authors.lastname: Ruben
authors.forename: Jose J
authors.initials: JJ
authors.lastname: Morales
authors.forename: Kenneth L
authors.initials: KL
authors.lastname: Rinehart
authors.forename: David P
authors.initials: DP
authors.lastname: Squillace
authors.forename: Matthew M
authors.initials: MM
authors.lastname: Ames
mesh_terms: D000818:Animals; D001189:Aryl Hydrocarbon Hydroxylases / Q000037:antagonists & inhibitors / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D001646:Bile / Q000737:chemistry; D019363:Cytochrome P-450 CYP1A1 / Q000378:metabolism; D019388:Cytochrome P-450 CYP1A2 / Q000378:metabolism; D051544:Cytochrome P-450 CYP3A; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D018076:DNA, Complementary / Q000235:genetics; D004149:Dioxoles / Q000009:adverse effects / Q000737:chemistry / Q000378:metabolism / Q000493:pharmacokinetics*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005260:Female; D006207:Half-Life; D006801:Humans; D007106:Immune Sera; D007546:Isoquinolines / Q000009:adverse effects / Q000737:chemistry / Q000378:metabolism / Q000493:pharmacokinetics*; D008297:Male; D008387:Marine Toxins / Q000009:adverse effects / Q000737:chemistry / Q000378:metabolism / Q000493:pharmacokinetics*; D008862:Microsomes, Liver / Q000201:enzymology*; D015394:Molecular Structure; D009249:NADP / Q000494:pharmacology; D010089:Oxidoreductases, N-Demethylating / Q000037:antagonists & inhibitors / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D020033:Protein Isoforms / Q000037:antagonists & inhibitors / Q000378:metabolism; D051381:Rats; D011916:Rats, Inbred F344; D011993:Recombinant Fusion Proteins / Q000378:metabolism; D012727:Sex Characteristics; D013250:Steroid Hydroxylases / Q000235:genetics / Q000378:metabolism; D013379:Substrate Specificity; D044005:Tetrahydroisoquinolines; D000077606:Trabectedin; D014561:Urochordata / Q000737:chemistry
chemical_list: D018076:DNA, Complementary; D004149:Dioxoles; D004791:Enzyme Inhibitors; D007106:Immune Sera; D007546:Isoquinolines; D008387:Marine Toxins; D020033:Protein Isoforms; D011993:Recombinant Fusion Proteins; D044005:Tetrahydroisoquinolines; C100350:ecteinascidin 729; D009249:NADP; D003577:Cytochrome P-450 Enzyme System; D013250:Steroid Hydroxylases; D001189:Aryl Hydrocarbon Hydroxylases; C113764:Cyp2c13 protein, rat; D019363:Cytochrome P-450 CYP1A1; D019388:Cytochrome P-450 CYP1A2; D051544:Cytochrome P-450 CYP3A; C029009:steroid hormone 7-alpha-hydroxylase; D010089:Oxidoreductases, N-Demethylating; D000077606:Trabectedin